hTERT promotes imatinib resistance in chronic myeloid leukemia cells: Therapeutic implications

Molecular Cancer Therapeutics

Volumn 10, Issue 5, 2011, Pages 711-719

  Deville, Laure ^a   Hillion, Josette ^a   Pendino, Frédéric ^a   Samy, Mona ^a   Nguyen, Eric ^a   Ségal Bendirdjian, Evelyne ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; RETINOIC ACID; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION TERMINATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEK293 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES; TELOMERASE; TRANSCRIPTION, GENETIC; TRETINOIN;

EID: 79956020200     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0979     Document Type: Article

References (32)

1. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
2. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
3. Gambacorti-Passerini C, Le Coutre P, Moligni L, Fanelli M, Bertazzoli C, Marchesi E, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23:380-94. (Pubitemid 28123720)
4. Kantarjian H SC, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, et al. International STI571 CML Study Group.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52. (Pubitemid 34815868)
5. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-505. (Pubitemid 30428483)
6. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80. (Pubitemid 32743979)
7. von Bubnoff N, Peschel C, Duyester J. Resistance of Philadelphia- chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 2003;17:829-38. (Pubitemid 36626307)
8. Hochhaus A, Kreil S, Corbin A, La Rosée P, Lahaye T, Berger U, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001;293:2163.
9. Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 2009;15:7519-29.
10. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-13. (Pubitemid 16213265)
11. Greider CW, Blackburn EH. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 1987;51:887-98.
12. Dudognon C, Pendino F, Hillion J, Saumet A, Lanotte M, Ségal-Bendirdjian E: Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance. Oncogene 2004;23:7469-74. (Pubitemid 39389688)
13. Fu W, Begley JG, Killen MW, Mattson MP. Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem 1999;274:7264-71.
14. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 2002;99:12606-11.
15. Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005;92:1881-91. (Pubitemid 40826137)
16. Tauchi T, Nakajima A, Sashida G, Shimamoto T, Ohyashiki JH, Abe K, et al. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin Cancer Res 2002;8:3341-7. (Pubitemid 35340707)
17. Bakalova R, Ohba H, Zhelev Z, Kubo T, Fujii M, Ishikawa M, et al. Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells. FEBS Lett 2004;564:73-84. (Pubitemid 38490703)
18. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070-9. (Pubitemid 30616875)
19. Tipping AJ, Mahon FX, Lagarde V, Goldman JM, Melo JV. Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood 2001;98:3864-7.
20. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8. (Pubitemid 29361801)
21. Pui JC, Allman D, Xu L, DeRocco S, Karnell FG, Bakkour S, et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 1999;11:299-308. (Pubitemid 29463238)
22. Pendino F, Flexor M, Delhommeau F, Buet D, Lanotte M, Ségal-Bendirdjian E. Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. Proc Natl Acad Sci U S A 2001;98:6662-7. (Pubitemid 32538273)
23. Ségal-Bendirdjian E, Jacquemin-Sablon A. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp Cell Res 1995;218:201-12.
24. Pendino F, Hillion J, Dudognon C, Delaunay J, Mourah S, Podgorniak MP, et al. Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL. Leukemia 2006;20:599-603.
25. Tarkanyi I, Dudognon C, Hillion J, Pendino F, Lanotte M, Aradi J, et al. Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. Leukemia 2005;19:1806-11. (Pubitemid 41486159)
26. Roth A, Vercauteren S, Sutherland HJ, Lansdorp PM. Telomerase is limiting the growth of acute myeloid leukemia cells. Leukemia 2003;17:2410-7. (Pubitemid 38072579)
27. Bakalova R, Ohba H, Zhelev Z, Ishikawa M, Shinohara Y, Baba Y. Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase-a potential reason for resistance to Glivec in chronic myelogenous leukaemia. Biochem Pharmacol 2003;66:1879-84. (Pubitemid 37352850)
28. Yamada O, Kawauchi K, Akiyama M, Ozaki K, Motoji T, Adachi T, et al. Leukemic cells with increased telomerase activity exhibit resistance to imatinib. Leuk Lymphoma 2008;49:1168-77. (Pubitemid 351943264)
29. Fu W, Killen M, Culmsee C, Dhar S, Pandita TK, Mattson MP. The catalytic subunit of telomerase is expressed in developing brain neurons and serves a cell survival-promoting function. J Mol Neurosci 2000;14:3-15. (Pubitemid 30368295)
30. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998;16:3323-30. (Pubitemid 28330432)
31. Kushner DM, Paranjape JM, Bandyopadhyay B, Cramer H, Leaman DW, Kennedy AW, et al. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol Oncol 2000;76:183-92. (Pubitemid 30067193)
32. Brassat U, Balabanov S, Bali D, Dierlamm J, Braig M, Hartmann U, et al. Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells. Exp Hematol 2011;39:66-76.